Background: It is well known that sleep disturbance is an integral symptom of schizophrenia. In recent studies, a deficit of delta sleep has been observed in schizophrenic patients. Antipsychotic drugs with serotonin (5-HT2) receptor-antagonistic properties are considered to have delta sleep promoting effects. We have investigated the effects of subchronic olanzapine treatment on sleep EEG in schizophrenic patients. Methods: The effects of administration of olanzapine (15 to 20 mg) on sleep were studied for four weeks in 10 male, drug-free patients suffering from schizophrenia with predominantly negative symptoms. Conventional sleep EEG parameters were investigated at baseline and after treatment with olanzapine for four weeks. Additionally, spectral power analysis of the EEG signal in distinct frequency bands was computed for different sleep stages. Psychopathology (PANSS, HAMD-17, HAMA) and side effects were assessed weekly. Results: All patients improved, as measured by PANSS global scores. Compared to baseline, there was a significant improvement of parameters of sleep efficiency and an increase of delta sleep as well as REM sleep. Regarding spectral power values, no significant differences between baseline and treatment conditions were found. Conclusions: Sleep improvement was due to parameters of sleep efficiency and delta sleep, which may be related to serotonin antagonistic properties of olanzapine.
References
1 American Psychiatric A ssociation. Diagnostic and Statistical Manual of Mental Disorders. 4th ed Washington, DC; American Psychiatric Press 1994
2
Baptista T, Kin N M, Beaulieu S, de Baptista E A.
Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.
Pharmacopsychiatry.
2002;
35
205-219
5
Bymaster F P, Calligaro D O, Falcone J F, Marsh R D, Moore N A, Tye N C, Seeman P, Wong D T.
Radioreceptor binding profile of the atypical antipsychotic olanzapine.
Neuropsychopharmacology.
1996;
14
87-96
6
Driver H S, Flanigan M J, Bentley A J, Luus H G, Shapiro C M, Mitchel D.
The influence of ipsapirone, a 5-HT1A agonist, on sleep patterns of healthy subjects.
Psychopharmacology.
1995;
117
186-192
7
Dugovic C, Wauquier A, Janssen P A.
Differential effects of the new antipsychotic risperidone on sleep and wakefulness in the rat.
Neuropharmacology.
1989;
28
1431-1433
8
Eschweiler G W, Bartels M, Langle G, Wild B, Gaertner I, Nickola M.
Heart-rate variability (HRV) in the ECG trace of routine EEGs: fast monitoring for the anticholinergic effects of clozapine and olanzapine?.
Pharmacopsychiatry.
2002;
35
96-100
10
Frieboes R -M, Murck H, Antoijevic I, Kraus T, Hinze-Selch D, Pollmächer T, Steiger A.
Characterization of the sigma ligand panamesine, a potential antipsychotic, by immune response in patients with schizophrenia and by sleep-EEG changes in normal controls.
Psychopharmacology.
1999;
141
107-110
11
Ganguli R, Reynolds C F, Kupfer D J.
EEG sleep in young, never medicated, schizophrenic patients: a comparison with delusional and nondelusional depressives and with healthy controls.
Arch Gen Psychiat.
1987;
44
36-45
17
Lewis C F, Tandon R, Shipley J E, DeQuardo J R, Jibson M, Taylor S F, Goldman M.
Biological predictors of suicidality in schizophrenia.
Acta Psychiat Scand.
1996;
94
416-420
19 Rechtschaffen A, Kales A. A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects. Washington, DC: Superintendent of Documents, U.S. Government Printing Office 1968
20
Riemann D, Hohagen F, Fleckenstein P, Schredl M, Berger M.
The cholinergic REM induction test with RS86 after scopolamine treatment in healthy subjects.
Psychiat Res.
1991;
38
247-260
21
Riemann D, Hohagen F, Krieger S, Gann H, Müller W E, Olbrich R, Wark H J, Bohus M, Low H, Berger M.
Cholinergic REM induction test: muscarinic supersensitivity underlies polysomnographic findings in both depression and schizophrenia.
J Psychiat Res.
1994;
28
195-210
23
Sanger T M, Liebermann J A, Tohen M, Grundy S, Beasley C J r, Tollefson G D.
Olanzapine versus haloperidol treatment in first-episode psychosis.
Am J Psychiat.
1999;
156
79-87
24
Schuld A, Kühn M, Haack M, Kraus T, Hinze-Selch D, Lechner C, Pollmächer T.
A comparison of the effects of clozapine and olanzapine on the EEG in patients with schizophrenia.
Pharmacopsychiatry.
2000;
33
109-111
25
Sharpley A L, Vassallo C M, Cowen P J.
Olanzapine increases slow-wave sleep: evidence for blockade of central 5-HT2C receptors in vivo.
Biol Psychiat.
2000;
47
468-470
27
Tandon R, Shipley J E, Taylor S, Greden J F, Eiser A, DeQuardo J, Goodson J.
Electroencephalographic sleep abnormalities in schizophrenia. Relationship to positive/negative symptoms and prior neuroleptic treatment.
Arch Gen Psychiat.
1992;
49
185-194
28
Tollefson G D, Beasley C M, Tran P V, Street J S, Krueger J A, Tamura R N, Graffeo K A, Thieme M E.
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective disorders: results of an international collaborative trial.
Am J Psychiat.
1997;
154
457-456
29
Tollefson G D, Sanger T M.
Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol controlled trial with olanzapine.
Am J Psychiat.
1997;
154
466-474
30
Tollefson G D, Sanger T M, Lu Y, Thieme M E.
Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol.
Arch Gen Psychiat.
1998;
55
250-258
31
Virkkunen M, Wahlbeck K, Rissanen A, Naukkarinen H, Franssila-Kallunki A.
Decrease of energy expenditure causes weight increase in olanzapine treatment - a case study.
Pharmacopsychiatry.
2002;
35
124-126
32
Wetter T C, Lauer C J, Gillich G, Pollmächer T.
The electroencephalographic sleep pattern in schizophrenic patients treated with clozapine or classical antipsychotic drugs.
J Psychiat Res.
1996;
30
411-419
